Xylem Inc. filings document the regulatory disclosures of a public operating company focused on water solutions and resource management. Recent Form 8-K reports furnish quarterly and annual financial results, including press-release exhibits for orders, revenue, earnings measures and guidance-related disclosures.
Other Xylem filings record capital actions such as common-stock repurchase authorization, while definitive proxy materials cover governance, shareholder voting matters and executive compensation disclosures, including equity-award and pay-versus-performance information.
Peribere Jerome A reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Jerome A. Peribere reported an equity compensation grant. He received 1,711 shares of common stock as a restricted stock unit (RSU) award at a reference price of $116.88 per share under the Xylem 2011 Omnibus Incentive Plan.
The RSUs are scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders, with settlement deferred until February 1, 2028. Following the grant, Peribere holds 5,747 shares directly and 27,209 shares indirectly through the Jerome A Peribere 2016 Revocable Trust.
Morelli Mark D reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Mark D. Morelli received an award of 1,711 shares of common stock in the form of restricted stock units valued at $116.88 per share. These units are scheduled to vest in full on the trading day before the 2027 Annual Meeting of Shareholders, with settlement deferred until his Separation from Service. Following this award, he directly holds 8,026 shares, including additional shares from dividend reinvestment.
Harker Victoria D reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Victoria D. Harker received an equity grant of 1,711 shares of Common Stock as a compensation award. The award is structured as restricted stock units under the Xylem 2011 Omnibus Incentive Plan and is scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders. After this grant, she holds 18,586 Xylem shares directly, indicating a routine, plan-based addition rather than an open-market purchase.
Glatch Lisa reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Lisa Glatch received a grant of 1,711 shares of common stock as a restricted stock unit award. The units were valued at $116.88 per share on the grant date and are scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders. After this compensation-related award, she directly holds 6,874 Xylem shares.
FRIEL ROBERT F reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Robert F. Friel received an equity award in the form of 2,481 shares of common stock, reported as a grant of restricted stock units valued at $116.88 per share. After this award, he directly holds 38,706 shares, including amounts credited through dividend reinvestment.
The award was granted under the Xylem 2011 Omnibus Incentive Plan and is scheduled to vest in full on the trading day before the 2027 Annual Meeting of Shareholders. Friel has elected to defer settlement of this RSU award until his Separation from Service, meaning he will receive the underlying shares at that later time rather than at vesting.
ELLIS EARL RAY reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Earl Ray Ellis reported receiving an award of 1,711 shares of common stock as restricted stock units valued at $116.88 per share. These RSUs are scheduled to vest in full on the trading day before the company’s 2027 Annual Meeting of Shareholders.
Ellis has elected to defer settlement of this RSU award until Separation of Service, meaning the actual share delivery is postponed until he leaves service. After this grant and dividend reinvestment adjustments, he now directly holds 6,038 shares of Xylem common stock.
Xylem Inc. senior vice president and chief accounting officer Geri-Michelle McShane reported an open-market sale and an option exercise involving the company’s common stock. She sold 4,269 shares at a weighted average price of $117.46 per share, with individual trades ranging from $117.42 to $118.17.
On the same date, she exercised stock options to acquire 3,147 shares of common stock at an exercise price of $86.76 per share, fully exhausting that option grant. After these transactions, she directly owns 3,605 shares of Xylem common stock.
Filer submitted a Form 144 notice for proposed sales of Common stock. The filing lists Fidelity Brokerage Services LLC as the selling broker and records multiple restricted‑stock vesting entries and an option‑related line. The excerpt shows the numeric entries 4272, 501457.48, and 237693493 alongside 05/07/2026 and NYSE.
Xylem Inc. director Jerome A. Peribere executed an open-market purchase of 1,210 shares of common stock at $116.61 per share through the Jerome A Peribere 2016 Revocable TR, an indirect ownership vehicle.
Following this transaction, his indirect holdings through the trust total 27,209 common shares, while a separate line shows 4,036 common shares held directly. The scale of the purchase is modest relative to his overall reported position, indicating a routine addition rather than a transformational change in ownership.
Xylem Inc. ownership disclosed: Vanguard Capital Management reports beneficial ownership of 18,193,892 shares of Common Stock, representing 7.48% of the class as reported. The filing states Vanguard has sole dispositive power for 18,193,892 shares and sole voting power for 2,376,964 shares. The report is signed and dated 04/30/2026.